Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
Manage episode 308266970 series 1058605
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what’s showing the most promise next. Clinical and research updates are combined with case-based demonstrations of how to address common challenges and make the most of the latest treatment options. Upon completion of this accredited CE activity, participants should be better able to: Review the role of immunotherapy in SCLC, rationale for using immune checkpoint inhibitors (ICIs) as part of first-line treatment of ES-SCLC, and emerging concepts on the integration of ICIs into multimodal therapy in LS-SCLC, Evaluate the latest data and emerging prospects in biomarker testing and subtyping in SCLC that may help to predict response to immunotherapy, Implement current guidelines, multidisciplinary strategies, and shared decision-making to ensure equitable care, early detection, and optimal management of patients with SCLC, Translate the latest safety and efficacy data on available and emerging immune-based treatment strategies in SCLC to individualize ICI therapy in clinical practice or through clinical trial enrollment.